We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-6.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$20.6B
AUM Growth
-$2.22B
Cap. Flow
+$62.6M
Cap. Flow %
0.3%
Top 10 Hldgs %
83.49%
Holding
126
New
5
Increased
17
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
TRDA icon
Entrada Therapeutics
TRDA
+$114M
2
INCY icon
Incyte
INCY
+$108M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$46.7M
4
TSVT
2seventy bio
TSVT
+$26M
5
TVTX icon
Travere Therapeutics
TVTX
+$17.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$66.1M
2
FLGT icon
Fulgent Genetics
FLGT
+$17.5M
3
BLUE
bluebird bio
BLUE
+$16M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$12.9M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$11.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.22%
2 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KZR
101
DELISTED
Kezar Life Sciences
KZR
$2.33M 0.01%
13,968
– –
BNR
102
Burning Rock Biotech
BNR
$103M
$1.99M 0.01%
20,913
– –
CYPH
103
Cypherpunk Technologies Inc
CYPH
$153M
$1.81M 0.01%
55,971
– –
HOOK
104
DELISTED
HOOKIPA Pharma
HOOK
$1.63M 0.01%
70,048
– –
GMDA
105
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$1.55M 0.01%
610,626
– –
SERA icon
106
Sera Prognostics
SERA
$84.4M
$1.39M 0.01%
201,562
– –
NEXI
107
DELISTED
NexImmune, Inc. Common Stock
NEXI
$1.36M 0.01%
11,765
– –
TARA icon
108
Protara Therapeutics
TARA
$228M
$1.35M 0.01%
199,671
– –
OYST
109
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$1.12M 0.01%
61,424
– –
LOGC
110
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$1.04M 0.01%
451,478
– –
FHTX icon
111
Foghorn Therapeutics
FHTX
$420M
$1.03M 0.01%
+45,027
New +$647K
EVFM
112
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$1.01M ﹤0.01%
179,807
– –
SRZNW
113
DELISTED
Surrozen Inc Warrant
SRZNW
$958K ﹤0.01%
833,333
– –
PASG icon
114
Passage Bio
PASG
$14.3M
$744K ﹤0.01%
5,858
– –
INZY
115
DELISTED
Inozyme Pharma
INZY
$730K ﹤0.01%
106,999
– –
BLCM
116
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$371K ﹤0.01%
249,123
– –
AUPH icon
117
Aurinia Pharmaceuticals
AUPH
$2.22B
– –
-520,523
Closed -$11.5M
MIRM icon
118
Mirum Pharmaceuticals
MIRM
$5.87B
– –
-647,313
Closed -$12.9M
MREO
119
Mereo BioPharma
MREO
$46.4M
– –
-292,692
Closed -$708K
AMYT
120
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
– –
-518,380
Closed -$6.24M
XLRN
121
DELISTED
Acceleron Pharma
XLRN
– –
-22,430
Closed -$3.86M
1 2 3 4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2021 Portfolio in Review

As of Q4 2021, Julian Baker held 126 positions worth $20.6B, down 9.7% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker's Q4 2021 filing shows 5 new, 17 increased, 8 reduced and 5 closed positions. Its largest new stake was Entrada Therapeutics: 4,704,419 shares worth $80.5M. The largest sale was Seagen Inc. Common Stock, an estimated $66.1M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q4 2021 buy was Entrada Therapeutics: 4,704,419 shares worth $80.5M.
  • Julian Baker added most to Incyte in Q4 2021, an estimated $108M increase.
  • Julian Baker's biggest Q4 2021 reduction was Seagen Inc. Common Stock, cutting an estimated $66.1M.
  • Julian Baker fully exited Mirum Pharmaceuticals in Q4 2021, selling an estimated $12.9M.
  • Julian Baker's ten largest holdings make up 83% of its $20.6B portfolio in Q4 2021.
  • Julian Baker opened 5 new positions and closed 5 in Q4 2021.
  • Julian Baker's portfolio value fell 9.7% quarter-over-quarter to $20.6B.

Based on Baker Bros. Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.